(IMM) ImmuPharma

Summary

Trade long or short on this share now through an Interactive Investor Spread Bet or CFD

Current Market Information

Time: 16:44

Bid	77.00
Ask	79.00
Price	78.00
Previous	78.00
Change	+1 (+1.28%)
Last Trade	79 (15:57:58)
Trading Vol.	67,876
Today's High	79.00
Today's Low	78.80

52 Wk Low	61.18
52 Wk Low	(15/07/2011)
52 Wk High	101.00
52 Wk High	(08/11/2011)
52 Wk Change	+0.75
52 Wk Change	(+0.97%)
4 Wk Volume	2,175,947
ISIN Number	GB0033711010
Currency	GBX

More Trades Info

Performance Graph
3 Month closing prices

More Chart Options

Fundamentals
Operating profit (m)

More IMM Research

Holdings
Buyers of IMM also buy

More Detail

Sector Heat Map

1 Month biggest movers

Sectors Analysis

Recent Regulatory News

Headline

Source

24-01-12

Immupharma PLC - Director's Dealings

RNS

08-11-11

Immupharma PLC - Notification of Major Interest in Shares

RNS

RNS Number : 6925R

Immupharma PLC

08 November 2011




TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ		Immupharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights			X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	Rhone Trustees (Switzerland) SA
4. Full name of shareholder(s) (if different from 3.):^iv	Same as above
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	4 November 2011
6. Date on which issuer notified:	7 November 2011
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	4%

8. Notified details:

A: Voting rights attached to shares ^{viii, ix}

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights ^x

Direct

Direct ^xi

Indirect ^xii

Direct

Indirect

Ordinary shares

3,111,000

3,386,000

4.15%

GB0033711010

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date ^xiii

Exercise/
Conversion Period ^xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date ^xvii

Exercise/
Conversion period ^xviii

Number of voting rights instrument refers to

% of voting rights ^{xix, xx}

N/A

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,386,000

4.15%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^xxi
N/A

Proxy Voting:
10. Name of the proxy holder:		N/A
11. Number of voting rights proxy holder will cease to hold:		N/A
12. Date on which proxy holder will cease to hold voting rights:		N/A

13. Additional information:	Rhone Trustees (Switzerland) SA has replaced Pictet Overseas Trust Corporation Ltd as trustee.
14. Contact name:	Tracy Weimar, Company Secretary
15. Contact telephone number:	020 7152 4080

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLLLFSLLLLTIIL

03-11-11

Immupharma PLC - LupuzorT granted approval to start phase III

RNS

RNS Number : 4007R

Immupharma PLC

03 November 2011

FOR IMMEDIATE RELEASE 3 NOVEMBER 2011

Immupharma plc

ImmuPharma's Lupuzor™ granted approval to start phase III and Fast Track designation by the FDA

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to provide an update on the development status of its Lupus drug candidate Lupuzor™.

Following ImmuPharma's IND (Investigational New Drug) filing with the FDA and the successful completion of the phase IIb study run by ImmuPharma, the Company licensed the global rights of Lupuzor™ to Cephalon in return of $45m upfront as part of a deal worth $500m plus royalties on product sales. As part of the deal, Cephalon became responsible for the continuation of development and as part of the overall development programme, they commenced an additional phase IIb study with a different formulation, which is still ongoing.

ImmuPharma recently regained rights to Lupuzor™, due to the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd. Following the review of information from Cephalon the Company is pleased to report the highlights of Lupuzor's™ development status:

· An "End of Phase 2" meeting package with ImmuPharma's phase IIb data was submitted to the FDA and the FDA responded to all the questions.

· The IMPD (Investigational Medicinal Product Dossier) submitted via the Voluntary Harmonized Procedure (VHP) in the EU was approved.

· The Scientific Advice meeting with the European Medicines Agency (EMA) was held; the recommendations were very similar to those in the FDA's "End of Phase 2" responses. Recommendations were incorporated into the phase III pivotal programme.

· The Japanese equivalent authorities (PMDA) have agreed to the initiation of clinical trials in Japan.

· The FDA has granted Lupuzor™ the approval to start phase III with a Special Protocol Assessment ("SPA").

· The FDA has granted Lupuzor™ "Fast Track" designation.

· The commercial validation batches of the active ingredient of Lupuzor™ necessary for phase III have already been manufactured.

ImmuPharma is now in discussions with pharmaceutical companies for a corporate deal regarding Lupuzor™.

Commenting on the positive update and the prospects for Lupuzor™, ImmuPharma's Chief Executive Officer, Dimitri Dimitriou, said:

"We are excited about the prospects of Lupuzor™, its progress in development and the approvals of the authorities in the US, Europe and Japan regarding its progression to the final stage of testing. The interest we are seeing already from pharma companies as potential partners gives us great confidence."

For further information, please contact:

ImmuPharma PLC:

Dimitri Dimitriou, Chief Executive Officer +44 (0) 20 7152 4080

Buchanan Communications

Lisa Baderoon + 44 (0) 7721 413 496
Mark Court +44 (0) 20 7466 5000

Panmure, Gordon & Co., NOMAD & Broker

Andrew Burnett, Hannah Woodley +44 (0) 20 7459 3600

Espirito Santo Investment Bank, Joint Broker

James Bromhead, Richard Crawley +44 (0) 20 7456 9191

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGGQUGUPGGBP

01-11-11

Immupharma PLC - Notification of Major Interest in Shares

RNS

RNS Number : 2412R

Immupharma PLC

01 November 2011


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES ⁱ

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ			Immupharma Plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	Change of custodian			X
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ		M&G Investment Funds 3
4. Full name of shareholder(s) (if different from 3.):^iv		State Street Noms Ltd A/C GMIQ
5. Date of the transaction and date on which the threshold is crossed or reached: ^v		3 October 2011
6. Date on which issuer notified:		4 October 2011
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}		See item 13

8. Notified details:

A: Voting rights attached to shares ^{viii, ix}

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights ^x

Direct

Direct ^xi

Indirect ^xii

Direct

Indirect

GB0033711010

7,600,000

9.32%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date ^xiii

Exercise/
Conversion Period ^xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date ^xvii

Exercise/
Conversion period ^xviii

Number of voting rights instrument refers to

% of voting rights ^{xix, xx}

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

7,600,000

9.32%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^xxi


Proxy Voting:
10. Name of the proxy holder:		N/A
11. Number of voting rights proxy holder will cease to hold:		N/A
12. Date on which proxy holder will cease to hold voting rights:		N/A

13. Additional information:	Disclosure due to change in registration details as listed above in item 4. However, this has not changed the overall notifiable position.
14. Contact name:	Tracy Weimar, Company Secretary
15. Contact telephone number:	020 7152 4080

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLLLFLILALLIIL

More news

Post New Message

Latest Messages
Date/Time	Subject	Author
Result Pages: 1
10:05	Re: Cancer Drug History	Divmad


	View Author's profile Add to favourites Ignore Author's posts
Looking forward to your report back on tomorrow's meeting. More View thread 27 Respond Login to Vote up
07:47	Re: Cancer Drug History	sicilian_kan


	View Author's profile Add to favourites Ignore Author's posts
Agreed. They have had years to buy shares. Why now? They didn't buy to prop the shares up in 2009 after the spike. Bought on the open market too and not through other means, e.g. options. In my view, the buys have to be positive, though of course they do not guarantee anything as I have seen elsewhere before. In addition, the directors (generally) have been sharp before such as the introducing "liquidity" to the market sales in 2009 - between the interim and final first Phase IIb trial results. More View thread 27 Respond Login to Vote up New enhanced Spread Betting platform. Find out more.
07:16	Re: Cancer Drug History	Divmad	1


	View Author's profile Add to favourites Ignore Author's posts
I take it as a positive, SK, that two directors knowledgeable about Lupuzor and the Phase IIb interim results, have decided recently to buy shares in the company. I don't believe they did it for a publicity stunt! More View thread 27 Respond Login to Vote up New enhanced Spread Betting platform. Find out more.
Tue 22:21	Re: Cancer Drug History	sicilian_kan


	View Author's profile Add to favourites Ignore Author's posts
For cash deal read "carp" deal. More View thread 27 Respond Login to Vote up

The contents of the postings summarised here represents the opinions of the authors and not of Interactive Investor Trading Limited.
They have not been approved or issued by Interactive Investor Trading Limited.

More messages

(IMM) ImmuPharma

Summary

Editor's Pick:

Editor's Pick:

Editor's Pick:

Editor's Pick:

Editor's Pick:

Editor's Pick:

Editor's Pick:

Editor's Pick:

Editor's Pick:

Editor's Pick:

Share

Information

Connect

Categories

Secondary links